In this scenario, the pivotal involvement of the insulin-mediated pathway in determining the ability of DR to induce anti-tumor effects supports the hypothesis that drugs that ameliorate insulin resistance in type 2 diabetes might be beneficial in preventing cancer, even in non-diabetic patients. This evidence concerns the gene INS and neoplasm.